Home › ACADIA Pharmaceuticals Receives FDA Breakthrough Therapy Designation For NUPLAZID (Pimavanserin) For Parkinson's Disease Psychosis
 

Keywords :   


ACADIA Pharmaceuticals Receives FDA Breakthrough Therapy Designation For NUPLAZID (Pimavanserin) For Parkinson's Disease Psychosis

2014-09-03 11:32:21| drugdiscoveryonline Home Page

ACADIA Pharmaceuticals Inc. a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in neurological and related central nervous system disorders, recently announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to NUPLAZID (pimavanserin) for the treatment of Parkinson’s disease psychosis

Tags: disease therapy receives designation

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
29.06Atlantic Tropical Weather Outlook
29.06Eastern North Pacific Tropical Weather Outlook
28.06What we learned from IT expert at Post Office inquiry
28.06M&S to launch clothing repairs service
28.06Tropical Depression Two Graphics
28.06Tropical Depression Two Public Advisory Number 1
28.06Summary for Tropical Depression Two (AT2/AL022024)
28.06Tropical Depression Two Forecast Advisory Number 1
More »